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6/j.bAs more efficient agents for stem cell mobilization are being developed, there is an urgent need to definewhich
patient population might benefit from these novel drugs. For a precise and prospective definition of ‘‘poor mo-
bilization’’ (PM), we have analyzed the efficiency ofmobilization in patients intended to receive autologous trans-
plantation at our center in the past 6 years. Between January 2003, and December 2008, 840 patients with the
following diagnoseswere scheduled to undergo leukapheresis: multiplemyeloma (MM, n5 602) and non-Hodg-
kin lymphoma (NHL,n5 238).Mostpatientsmobilized readily: close to85%of thepatientshad a level of 20/mL to
.500/mL ofCD341 cells at the peakof stimulation.Of the 840 patients, 129 (15.3%)were considered tobe PMs,
defined as patientswho had a peak concentration of\20/mL of CD341 cells upon stimulation with granulocyte-
colony stimulating factor (G-CSF) subsequent to induction chemotherapy appropriate for the respective disease.
Among them, 38 (4.5%) patients had CD341 levels between 11 and 19/mL at maximum stimulation, defined as
‘‘borderline’’ PM, 49 (5.8%) patients had CD341 levels between 6 and 10/mL, defined as ‘‘relative’’ PM, and 42
patients (5%) with levels of\5/mL, defined as ‘‘absolute’’ PM. There was no difference in the incidence of PM
between patients with MM versus those with NHL. Sex, age, body weight (b.w.) and previous irradiation ther-
apy did not make any significant difference. Only the total number of cycles of previous chemotherapy
(P 5 .0034), and previous treatment with melphalan (Mel; P 5 .0078) had a significant impact on the ability
to mobilize. For the good mobilizers, the median time to recovery of the white blood cells (WBCs) to 1.0/
nL or more was 13 days with a range of 7 to 22 days, whereas for the PM group it was 14 days with a range
of 8 to 37 days. This difference was statistically not significant. The median time to recovery of the platelets
counts to an unmaintained level of.20/nL was 11 days with a range of 6 to 17 days for the good mobilizers,
whereas for the PM it was 11 days with a range of 7 to 32 days. Again, this difference was not significant. The
majority of the patients today intended for autologous transplantations were able to mobilize readily. As long
as$2.0 106 of CD341 cells/kg b.w. have been collected, PM was not associated with inferior engraftment.
Biol Blood Marrow Transplant 16: 490-499 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Stem cell mobilization, Stem cell transplantation, Poor mobilizerINTRODUCTION
Peripheral blood stem cells (PBSCs) have largely
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bmt.2009.11.012plantations, and have become the source of stem cells
in the majority of allogeneic transplantations. In the
mid-1980s several institutions demonstrated that
PBSCs could represent viable alternatives to BM cells
as a source of hematopoietic stem and progenitor cells
for autologous transplantation [1-5]. PBSCs offer sev-
eral advantages such as harvest of cells without general
anesthesia, elimination of pain after multiple aspira-
tions from the BM, and above all, they are associated
with more rapid engraftment [6-8].
In the meantime, autologous PBSC transplanta-
tion is the treatment of choice within the primary
treatment strategy for multiple myeloma (MM)
[9-12], and is also the preferred treatment option for
relapsed/refractory B cell non-Hodgkin lymphoma
(NHL) [13-17]. The main disadvantage of PBSCs is
that they exist in the circulation in very small numbers.
Less than 0.06% of white blood cells (WBCs) are
Biol Blood Marrow Transplant 16:490-499, 2010 491Poor Mobilization of HSCCD341, which is a cell surface protein that is expressed
on hematopoietic stem (HSCs) and progenitor cells
and represents a reliable surrogate marker for hemato-
poietic progenitor cells [18-20].
HSCsandprogenitor cells reside in theBMand they
have to be mobilized into the circulation prior to being
collected by apheresis. The number of apheresis proce-
dures needed and the success of transplantation are de-
termined by the efficiency of stem cell mobilization
([21,22], review in [23]). Stem cells adhere to their BM
niche by interactions between SDF1a, which is
produced by BM stromal cells, and CXCR4, which is
expressed on CD341 cells [24,25]. Granulocyte col-
ony-stimulating factor (G-CSF), which has been in clin-
ical use for more than 2 decades, mobilizes stem cells
from the BM niche by secretion of neutrophil-
associated extracellular proteases, such as MMP-9,
which subsequently releases HSC from their niche
[26]. In contrast, Plerixafor (formerly known as
AMD3100) is a novel mobilization agent that directly
inhibits the CXCR4-SDF1a cell-cell interaction
[27,28].
Several stem cell mobilization strategies have been
employed since development of PBSC transplantations.
In the early days of transplantation, stem cell mobiliza-
tionwas achievedwith chemotherapeutic drugs because
the use of chemotherapy causes a significant increase in
the number of PBSCs at the time of recovery [1,3,5].
However, many patients failed to mobilize sufficient
PBSCs for transplantation in response to chemother-
apy. In the late 1980s, hematopoietic growth factors
such as granulocyte-macrophage colony-stimulating
factor (GM-CSF) andG-CSF have beenmade available
[29-33]. Their administration subsequent to chemo-
therapy has been shown to mobilize PBSCs efficiently
[34]. G-CSF and GM-CSF were approved for use as
HSC mobilizing agents, but G-CSF (in combination
with chemotherapy or alone) has become standard
(review in [23]). Unfortunately, some patients fail to
mobilize sufficient numbers of PBSCs for transplanta-
tion in response to G-CSF with or without chemother-
apy [22,30,35-39]. There is thus far no consensus on the
definition of poor mobilizers (PM).
Based on this retrospective analysis of 840 patients
who were mobilized with chemotherapy and growth
factors with the intent of autologous transplantation
at a single center, we have provided a more precise def-
inition of ‘‘poor’’ mobilization, and have evaluated the
incidence, risk factors, and impact on transplantation
outcome in a modern setting.PATIENTS AND METHODS
Patients
We analyzed data from 602 patients with MM and
238 patients withNHL, who were scheduled to receiveautologous PBSC transplantation (PBSCT) between
2003 and 2008 at theDepartment of InternalMedicine
V in Heidelberg. Retrospective data analysis was
approved by the Ethics Committee of theMedical Fac-
ulty of Heidelberg. The median age was 59 years, with
a range from 12 to 75 years (MM: 60 years, range:
27-75 years; NHL: 54 years, range: 12-74 years).
PBSCs were mobilized with chemotherapy (CT) fol-
lowed by G-CSF. The appropriate regimen as CT
was used to reduce the tumor burden and to facilitate
PBSC harvesting.Mobilization Regimens
For patients with MM, the following chemother-
apy regimens were used for remission induction and
for mobilization. CAD (cyclophosphamide [Cy]
1,000 mg/m2/d day 1, doxorubicin 15 mg/m2/d days
1-4, dexamethasone 40 mg/day orally days 1-4),
TCED (thalidomide 400 mg/day orally, etoposide
40 mg/m2/d days 1-4, Cy 400 mg/m2/d days 1-4,
dexamethasone 40 mg/day orally days 1-4), HD-Cy
(Cy 2000 mg/m2/day days 1-2) or lenalidomide/dexa-
methasone (lenalidomide 25 mg/day orally days 1-21,
dexamethasone 20 mg/day orally days 1-4, 9-12
and 17-20).
For patients with NHL, the following regimens
were used for remission induction and, in case chemo-
sensitivity is demonstrated, the same regimen will be
used for mobilization: Dexa-BEAM (dexamethasone
3  8 mg/day days 1-10, carmustine 60 mg/m2/day
day 2, melphalan [Mel] 30 mg/m2/day day 2, cytara-
bine 2  100 mg/m2/day days 3-6, etoposide 75 mg/
m2/day days 3-6), R-Dexa-BEAM (rituximab 375
mg/m2/day day 0, Dexa-BEAM), CHOP (Cy 750 mg/
m2/day day 1, doxorubicin 50 mg/m2/day day 1, vin-
cristine 1.4 mg/m2/day [max. 2.0 mg] day 1, predni-
sone 100 mg/day days 1 -5), CHOEP (CHOP plus
etoposide 100 mg/m2/day days 1-3), R-CHOP (ritux-
imab 375 mg/m2/day day 0, CHOP), R-CHOEP (rit-
uximab 375 mg/m2/day day 0, CHOP plus etoposide
100 mg/m2/day days 1-3), DHAP (dexamethasone
40 mg/day days 1-4, cisplatin 100 mg/m2/day day 1,
cytarabine 2  2000 mg/m2/day day 2), R-DHAP
(rituximab 375 mg/m2/day day 0, DHAP) or HD-Cy
(Cy 2000 mg/m2/day days 1-2).
All patients received G-CSF starting 4 to 5 days af-
ter completion of chemotherapy in dosages of 5-10 mg/
kg/day subcutaneously (s.c.) until the end of the collec-
tion period.
If the patients failed to reach target collections,
they could have a second or third attempt to mobilize
an adequate amount of stem cells for transplantation.
The following options were adopted: (1) another
attempt to mobilize with chemotherapy and G-CSF;
(2) G-CSF alone after a ‘‘rest’’ period of at least
21 days without chemotherapy; (3) BM harvest as an
492 Biol Blood Marrow Transplant 16:490-499, 2010P. Wuchter et al.alternative; (4) Plerixafor within a compassionate use
program.
Immunofluorescence Staining and Flow
Cytometry
PB CD341 cell measurements were started after
a WBC count of $5.0  109/L was reached. CD341
cell measurements during mobilization were per-
formed daily on weekdays. The absolute number of
CD341 cells was evaluated by flow cytometry using
a FACScan analyzer (Becton Dickinson; Heidelberg,
Germany) and the appropriate isotype-matched nega-
tive control, as has been described previously [19,20].
We used a forward scatter versus CD45 fluorescence
dot plot to discriminate between the smallest hemato-
poietic cell population and erythrocytes or debris. The
percentage of CD341 cells relative to the percentage
of CD45’ cells and the absolute number of CD341
cells were calculated as previously described.
To increase the sensitivity of progenitor cell detec-
tion in steady-state PB, a gated acquisition on CD341
cells was performed [18,19]. CD341 PBSCs were
monitored daily as soon as the WBC recovered
($5.0  109/L PB). Apheresis was scheduled to start
when there were .20 CD341 cells/mL of PB. If this
target was not reached, other parameters, like increas-
ing WBC or platelet reconstitution, were used to
decide on leukapheresis attempts. The minimal collec-
tion target was 2.0  106 CD341 cells/kg body weight
(b.w). Our aim was to process 3 times the patient’s
blood volume daily through an indwelling central or
peripheral venous catheter using a cell separator (Spec-
tra; COBE Laboratories, Heimstetten, Germany).
Each leukapheresis product was cryopreserved in
nitrogen until the day of transplantation.
Collection of PBSC
Harvesting was performed with a COBE Spectra
Blood Cell (Spectra; COBE Laboratories). We started
the leukapheresis procedure if the CD341 counts in
PB were .20/mL. In cases when the leukocyte count
under daily G-CSF-stimulation after chemotherapy
has reached a plateau for more than 2 days, the patients
underwent a leukapheresis procedure attempt even if
the CD341 count was \20 cells/mL. All patients
described in this study underwent leukapheresis.
Definition of PM
Patients with CD341 levels of\20/mL in periph-
eral blood at maximum stimulation were considered
to be PM. This group was further subdivided: patients
with CD341 levels between 11 and 19/mL were
defined as ‘‘borderline’’ PM; patients with CD341
levels between 6 and 10/mL were defined as ‘‘relative’’
PM, and patients with levels of\5/mL were regarded
as ‘‘absolute’’ PM.Reconstitution
The definitions of engraftment and supportive care
after autologous transplantation has been described in
detail previously [17,19,20,34]. Hematopoietic recon-
stitution was defined from the day of PBSC reinfusion
(day 0) until leukocyte counts were stable at .1.0 /nL
for at least 3 days. The time to platelet reconstitution
over 20/nL was defined as the number of days for
platelets to be stably above 20/nL without any transfu-
sion. No patients received G-CSF after high-dose
chemotherapy and transplantation.
Statistical Analysis
The results are presented as median values,
ranges, and correlation coefficients, where applicable.
The relationships between different hematologic pa-
rameters of the PB and leukapheresis products were
analyzed by correlational statistics. Pearson’s sample
correlation coefficient and the corresponding P value
for the null hypothesis of no correlation were
calculated.
On multivariate logistic regression analysis we
studied the impact of age, sex, b.w., cycles of previous
chemotherapy cycles, and radiation therapy on stem
cell mobilization, and time to hematologic recovery
after transplantation.RESULTS
Incidence of PM
Between January 2003 toDecember 2008, 868 con-
secutive patients with the following diagnoses were
scheduled to undergo leukapheresis for autologous
transplantations: MM (n 5 602), NHL (n 5 238),
and Hodgkin disease (HD, n5 28). Because the num-
ber of patients with HD was small and only 2 of them
were classified as PMs, patients with HD were not in-
cluded in the final analysis, which was performed only
on those with MM and NHL. The major indications
for autologous transplantation have been focused on
these 2 diseases in the past 6 years.
Our group and other authors have previously dem-
onstrated the significant correlation between preleuka-
pheresis CD341 levels in circulating blood and the
absolute amount of CD341 cells collected in the leuka-
pheresis products [19-22]. This correlation is con-
firmed in this retrospective analysis of altogether 840
leukapheresis procedures (see Figure 1A and B) for
the first day of collection. Our data have provided con-
vincing evidence that the level of CD341 counts is
a reliable prospective parameter for estimation of suc-
cess of mobilization. Based on our own observations
and those reported in the literature, we have then de-
fined PM as patients who had a peak CD341 concen-
tration of\20/mL of CD341 cells upon stimulation
Figure 1. (A) Positive correlation between peak CD341 values in pe-
ripheral blood and harvested CD341 cells. The broken lines define the
95% confidence limits formean predicted values. (B) Positive correlation
between peak CD341 values in peripheral blood and harvested CD341
cells. The broken lines define the 95% confidence limits for individual
predicted values.
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appropriate for the respective disease.
Of the 840 patients with MM and NHL scheduled
to receive autologous transplants, 129 patients (15.3%)
had CD341 levels of\20/mL at maximum stimulation
and were therefore considered to be PM. This group
was further subdivided: 38 patients (4.5%) had
CD341 levels of between 11 and 19/mL, defined as
‘‘borderline’’ PM; 49 patients (5.8%) had CD341
levels of between 6 and 10/mL, defined as ‘‘relative’’
PM and 42 patients (5.0%) with levels of \5/mLwere defined as ‘‘absolute’’ PM. The clinical character-
istics of these patients are shown in Table 1.
Leukapheresis Products and Autologous
Transplantations
Among the 602 patients with MM, 516 patients
(85.7%) had CD341 levels of $20/mL at maximum
stimulation and were therefore classified as good
mobilizers. The goal of collecting 2.0  106 CD341
cells/kg b.w. was achieved with 1 to 3 leukapheresis
(median 5 1) procedures in these 516 patients (see
Table 2). Among the 29 borderline PM with MM,
the target number of CD341 cells could be collected
with 1 to 4 leukapheresis (median 5 2) procedures.
For the 29 relative PM, the target CD341 cell dose
of 2.0  106 cells/kg b.w. could be achieved with 1 to
5 procedures (median 5 3) in 25, that is, 86% of these
patients, whereas for the 28 absolute PM, only 12 of
them, that is, 43%, achieved the goal with 1 to 6 leuka-
pheresis procedures (median 5 4). Nevertheless 19 of
these absolute PM received a transplant. The differ-
ence of 7 patients can be explained by the fact that
we were able to collect between 1.5 to 1.9  106
cells/kg b.w. of CD341 as an autologous graft in 4
patients and these levels of CD341 cells were consid-
ered to be appropriate for the respective patients. In
3 further patients we were able to reach the collection
goal in a second mobilization attempt. All of them
engrafted.
Among the 238 patients with NHL, 195 patients
(81.9%) were classified as good mobilizers and the
goal of collecting 2.0  106 CD341 cells/kg b.w.
was achieved with 1 to 2 leukapheresis procedures
(median 5 1) in every everyone of the 195 patients.
Among the 9 borderline PM with NHL, the target
number of CD341 cells could be collected with 1 to
3 leukapheresis procedures (median 5 1) in all of the
9 patients. For the 20 relative PM, the target CD341
cell number was collected with 1 to 5 procedures
(median 5 3) in 13, that is, 65% of these patients,
whereas for the 14 absolute PM, only 5 of them, that
is, 36% achieved the goal with up to 6 leukapheresis
procedures (median 5 4). Three of these absolute
PM received ultimately a transplant (see Table 2).
Characterization of PMs
The percentage of patients classified as PMs for the
whole group is 15%. As reported in the literature, it is
controversial if a peak level of 10/mL or 20/mL of
CD341 cells should be considered as the threshold. If
a peak level of 10/mL is considered as threshold, 11%
instead of 15% were PMs. The correlation between
CD341 cell concentrations in peripheral blood with
the PBSC collection is depicted in Figure 1A and B.
Hence, we again confirm the previous observation
that pre-apheresis CD341 count predicts reliably the
Table 1. Clinical Features of Poor and Good Mobilizers
Poor mobilizer Good mobilizer
Total 129 15% 711 85%
- MM 86 14% 516 86%
- NHL 43 18% 195 82%
Sex (male : female) 81 : 48 422 : 289
Median age (years; range) 61 (19-75) 58 (12-74)
Previous irradiation 37 44% 23* 22%*
No. of previous chemotherapy cycles (median; range) 6 (1-20) 3* (1-6)*
MM indicates multiple myeloma; NHL, non-hodgkin lymphoma. only a subgroup of ‘‘good mobilizer’’ (n5103) was analyzed.
*only a subgroup of ‘‘good mobilizer’’ (n5103) was analyzed.
494 Biol Blood Marrow Transplant 16:490-499, 2010P. Wuchter et al.quality and quantity of collection. The distribution of
the preleukapheresis CD341 counts in peripheral
blood samples among the patients with MM and with
NHL is summarized in Figure 2A and B. Hence, close
to 70%of the patients had a level of 20/mL to 250/mLof
CD341 cells at the peak of stimulation. Levels as high
as .500/mL of CD341 cells have been recorded.
We have analyzed the relationship between poor
mobilizations with types of disease (MM versus
NHL), sex, age, b.w., previous irradiation, number of
cycles of previous combination chemotherapy, and
pretreatment with Mel among the 840 patients. The
results of univariant analysis are shown in Table 3.
There was no difference in the incidence of PM
between patients with MM versus those with NHL.
Sex, age, b.w. and previous irradiation therapy did
not make any difference. Only the number of cycles
of previous chemotherapy (P 5 .0034), and previous
treatment with Mel (P 5 .0078) had a significant im-
pact on the ability to mobilize. For example, PM
received a median of 6 cycles of chemotherapy,
whereas good mobilizers received a median of 3 cycles.Secondary Mobilization after Initial Failure
Secondary strategies to mobilize HSC from the 36
who failed to achieve an adequate collection included:
(1) Administration of another cycle of induction
chemotherapy and G-CSF: the goal of harvesting
2.0  106 CD341 cells/kg b.w. could be accomplished
in 7 of 21 of these patients. (2) G-CSF alone for 4 days
(up to 8 days of stimulation) after hematopoieticTable 2. Degrees of Poor Mobilizations and CD34+ Cells Collected
Total no.
of patients
MM (n5602) Peak level of CD34+ cells n %
- Good mobilizer >520 /mL 516 86%
- Borderline poor mobilizer 11-19 /mL 29 5%
- Relative poor mobilizer 6-10 /mL 29 5%
- Absolute poor mobilizer 0-5 /mL 28 5%
NHL (n5238) Peak level of CD34+ cells n %
- Good mobilizer >520 /mL 195 82%
- Borderline poor mobilizer 11-19 /mL 9 4%
- Relative poor mobilizer 6-10 /mL 20 8%
- Absolute poor mobilizer 0-5 /mL 14 6%
MM indicates multiple myeloma; NHL, non-hodgkin lymphoma.recovery from previous induction chemotherapy: the
goal could be achieved in 2 of the 9 patients thus mobi-
lized. (3) Plerixafor within the compassionate use pro-
gram: the goal was accomplished in 7 of 8 patients. In 1
patient only 1.78  106 CD341 cells/kg b.w. could be
harvested, but these cells were considered as sufficient
and appropriate for autologous blood stem cell trans-
plantation (ABSCT) for this patient, so that all 8 pa-
tients were transplanted successfully. (4) BM harvest
in lieu of collection of peripheral HSC in 5 patients:
seven of the 36 PMs underwent more than 1 secondary
attempt. The results are summarized in Figure 3.Engraftment Data
For comparisons in time to engraftment of leuko-
cytes and platelet counts between PMs and good
mobilizers, we have chosen 305 patients, age and sex
matched, from the ‘‘good mobilizers’’ group. We
have retrospectively retrieved their reconstitution
data and have compared them to those derived from
the PMs described in this study. After autologous
transplantation G-CSF was never administered in
any case. The correlation between peak concentration
of CD341 cells/mL before the first leukapheresis and
the reconstitution time among these patients (305
good mobilizers and 89 PMs transplanted) is shown
in Figures 4A and B.
For the goodmobilizers, the median time to recov-
ery of the WBC to 1.0/nL was 13 days, with a range of
7 to 22 days, whereas for the PM group it was 14 days,
with a range of 8 to 37 days. This difference wasPatients achieving collection
goal of 2.0 x10exp6 CD34+ cells /kg bw Patients transplanted
n % n %
516 100% 484 94%
29 100% 25 86%
25 86% 24 83%
12 43% 19 68%
n % n %
195 100% 150 77%
9 100% 5 56%
13 65% 11 55%
5 36% 3 21%
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Figure 2. (A) Peak CD341 values in peripheral blood at the time of leu-
kapheresis in patients with MM. (B) Peak CD341 values in peripheral
blood at the time of leukapheresis in patients with NHL.
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ery of the platelet counts to an unmaintained level of
.20/nL was 11 days with a range of 6 to 17 days for
the good mobilizers, whereas for the PMs it was 11
days with a range of 7 to 32 days. Again, this difference
was statistically not significant. The corresponding re-
constitution times, analyzed separately for the sub-
groups borderline PM, relative PM, and absolute PM
are summarized in Table 4.
In summary the reconstitution data suggest that as
long as 2.0 106 of CD341 cells/kg b.w. could be har-Table 3. Factors Affecting Quality of Mobilization
Wald Chi-Square Pr > Chi Sq
Sex 1.0211 0.3123
Age 2.2328 0.1351
Body weight 1.9791 0.1595
Mobilization with plerixafor 2.0911 0.1482
Previous chemotherapy with
melphalan
7.0688 0.0078
Previous irradiation therapy 0.0002 0.9878
No. of previous chemotherapy
cycles
8.6057 0.0034vested, poor mobilization was not associated with poor
engraftment.DISCUSSION
The development of strategies to promote release
ofHSC and progenitors from the BM into the circulat-
ing blood for clinical transplantation has evolved from
a highly experimental procedure in the mid-1980s to
standard of care for autologous transplantations (re-
view in [23]). The main advantage of PBSC transplan-
tation is the accelerated reconstitution compared to
BM transplantations (BMTs) [1-5]. The major disad-
vantage is that HSCs reside in the BM and have to be
mobilized into the circulation prior to being collected
by apheresis [1,23]. The number of apheresis proce-
dures needed and the success of transplantation are de-
termined by the efficiency of stem cell mobilization.
Before hematopoietic growth factors were devel-
oped in the late 1980s, stem cell mobilization was
achieved with chemotherapeutic drugs. After myelo-
suppressive chemotherapy, a significant increase in
the number of PBSCs at the time of recovery was
observed [1-5]. The yield was unpredictable, and
many patients had to undergo 4 to 6 leukapheresis
procedures before an adequate among was collected.
The availability of GM-CSF and G-CSF has greatly
revolutionalized the mobilization of PBSCs for autol-
ogous transplantations (review in [23]).
There were numerous reports on patients who
failed to mobilize sufficient numbers of PBSCs for
transplantation [36-43]. The incidence has been
reported to be between 5% and 40% [37-43]. There
is thus far also no consensus on the definition of
PMs. Some reports used a value of 1.0  106 CD341
cells/kg b.w., whereas others reported a threshold of
2.0  106 CD341 cells/kg b.w. [37-43] as the parame-
ter for poor mobilization. Using 2.0  106 CD341
cells/kg b.w. as the cutoff value, Pusic et al. [42] re-
ported a failure rate of 18.6% in patients who received
Figure 4. (A) Median time to recovery of theWBC to 1.0/nL in corre-
lation to peak CD341 cells/uL in peripheral blood at the time of leuka-
pheresis. (B) Reconstitution of platelets after ABSCT (ie, platelet count
$20/nL without transfusions for 3 days) in correlation to peak CD341
cells/mL in peripheral blood at the time of leukapheresis.
Table 4. Engraftment Data in Relationship to Mobilization
Median Minimum Maximum
Reconstitution of leukocytes (days after ABSCT)
- Good mobilizer 13 7 22
- Borderline poor mobilizer 15 10 22
- Relative poor mobilizer 13 8 21
- Absolute poor mobilizer 15 12 37
Reconstitution of platelets
- Good mobilizer 11 6 17
- Borderline poor mobilizer 11 9 14
- Relative poor mobilizer 11 7 32
- Absolute poor mobilizer 12 9 16
ABSCT indicates autologous blood stem cell transplantation.
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those who received G-CSF for the initial mobilization.
These authors have also defined 20/mL of CD341 cells
as the minimum threshold needed for a successful day
1 collection. They concluded that current mobiliza-
tion regimens are associated with a substantial failure
rate irrespective of underlying disease.
In an analysis of PMs among patients with recur-
rent or relapsed lymphoma at a single center (M.D.
AndersonCancer Center, Houston, Texas, USA)Hos-ing et al. [43] found that 29 (14.1%) of 206 patients
failed to mobilize adequately on first attempt. The
definition of poor mobilization was failure to collect
a minimum of 2.0  106 cells/kg b.w. of CD341 cells
in 4 leukapheresis procedures in this study.
Thus, most recent studies have adopted the defini-
tion of poor mobilization as inability to collect 2.0 
106 cells/kw b.w. of CD341 cells. However, this can
only be estimated retrospectively after leukapheresis
has been performed. There was also no clear-cut stip-
ulation on the number of leukapheresis procedures re-
quired to achieve this goal as a parameter to distinguish
good mobilizers from PMs. Fruehauf et al. [19,20]
have shown that there is a highly significant correlation
between the CD341 concentration in peripheral blood
and the potential to collect an adequate amount of
CD341 cells within 1 or up to 3 leukapheresis proce-
dures. We [34,44,45] have demonstrated that the opti-
mal window for collection of CD341 cells after
stimulation with G-CSF, with or without previous
chemotherapy, was just 3 to maximally 4 days after
reaching optimal stimulation. Given the present day
advances in development of standards and guidelines
for quality control of the PBSC products, there is an
increasing need for a better definition of poor mobili-
zation. Based on our previous reports [17,19,20,34,
44-46], and based on this retrospective analysis of
840 patients at our center who were mobilized with
chemotherapy and growth factors with the intent of
autologous transplantation, we propose a more precise
definition of poor mobilization and PMs. In the light
of recent development of new classes of mobilization
agents such as CXCR4 inhibitors, predictive factors
are urgently needed to discern those patients who
might likely derive benefit from the more efficient
mobilization agents.
According to the criteria thatwehave defined, of the
840 patients with MM and NHL scheduled to receive
autologous transplants, 129 patients (15.3%) were con-
sidered to bePMs.Among them, 38 patients (4.5%) had
CD341 levels of between 11 and 19/mL at maximum
stimulation, defined as ‘‘borderline’’ PM, 49 patients
(5.8%) had CD341 levels of between 6 and 10/mL,
Biol Blood Marrow Transplant 16:490-499, 2010 497Poor Mobilization of HSCdefined as ‘‘relative’’ PM, and 42 patients (5.0%) with
levels of\5/mL, defined as ‘‘absolute’’ PM.
In contrast to the reports of Pusic et al. [42] and
Hosing et al. [43], our retrospective analysis showed
that the majority of the patients were able to mobilize
readily. The median concentration of CD341 cells/
mL among the patients included in this study was
81/mL. A total of 2.2% of patients had a concentration
of.500CD341 cells/mLat the peak of stimulation and
85% of the patients had .20 CD341 cells/mL at the
time of maximum stimulation before leukapheresis.
We have also demonstrated unequivocally that there
was no significant difference between patients with
NHL or MM. Moreover, once an adequate amount
has been stimulated, CD341 cell numbers above
2.0  106 cells/kw b.w. of CD341 cells did not confer
more advantage in terms of engraftment of leukocytes
and platelets. The present data have confirmed our
previous observation that although higher doses of
CD341 cells (i.e. (or, that is), .6.5  106/kg b.w.)
might marginally, but significantly, shorten the time
to leukocyte and platelet recovery, stable engraftment
was achieved with transplantation of 2.0  106
CD341 cells /kg b.w. [47].
Similar to many others, our group has previously
shown that autologous BMTor PBSCTmight be asso-
ciated with long term side effects such as myelodyspla-
sia [48,49]. We have not been able to analyze the
differences in the long-term side effects between PMs
and good mobilizers yet. The present analysis is also
not powered to address these issues and they also
need to be addressed after longer follow-up period.
Secondary strategies to mobilize HSCs from the 36
patients included administration of another cycle of
induction chemotherapy combined with G-CSF,
G-CSF alone for 4 to 9 days upon hematopoietic
recovery from previous induction chemotherapy,
Plerixafor, and G-CSF within the compassionate use
program, and BMharvest. The best results were accom-
plished with Plerixafor and G-CSF, and the goal of col-
lecting 2.0 106CD341 cells/kgb.w.was accomplished
in 7 of 8 patients. All 8 patients who were remobilized
with Plerixafor and G-CSF received an autologous
transplantation and all 8 have achieved stable engraft-
ment. In the 1 patient who failed to reach the goal by
a narrowmargin, 1.78 106 CD341 cells/kg b.w. could
be harvested and he was transplanted successfully.
In the past 8 to 10 years, advances in stem cell re-
search has led to a better understanding of the signifi-
cance and the molecular mechanisms underlying the
adhesion of the primitive HSCs and progenitor cells
to the BM niche. Albeit many adhesion molecules
have been shown to play a role in maintenance of the
stem cells in the niche, interactions between SDF1a,
which is expressed by BM stromal cells, and CXCR4,
which is expressed onCD341 cells, have been identified
as a significant pathway for homing andmobilization ofCD341 cells [24,25,27,28]. In the meantime, a specific
inhibitor of CXCR42 SDF1a has been approved both
by the Food and Drug administration (FDA) and the
EuropeanMedicines Agency (EMEA) for mobilization
of HSCs. In clinical trials, mobilization of CD341 cells
from the bone marrow into the peripheral blood has
been reported to be augmented by single-dose adminis-
tration of Plerixafor after 4 days of G-CSF [50-54].
Studies inNHLandMMpatients showed that the com-
bination of G-CSF and Plerixafor (G 1 P) resulted in
a significant increase inCD341 cell yield after apheresis
compared to the administrationofG-CSFalone.More-
over, G1 P administration resulted in a rapid and sus-
tained neutrophil and platelet engraftment of the
mobilized HSCs [53,54]. In addition to an absolute in-
crease in overall CD341 cells upon Plerixaformobiliza-
tion, the proportion of CD341/CD382 subset, a more
primitive and potent progenitor cell population, was
also significantly elevated [50,51].
Whereas the relative role and the significance of
Plerixafor in the combinatorial mobilization will
need to be defined in the future, it is important to de-
fine which group of patients will derive the most ben-
efit from these novel agents. The first group of patients
that will benefit are the absolute PMs. Albeit 40% of
the absolute PM in this study were able to reach the
collection goal, they required a median of 4 leukaphe-
resis procedures. Thus, administering Plerixafor in ad-
dition to G-CSF in these patients will offer a much
higher chance of successful collection for these pa-
tients with fewer leukapheresis procedures, and hence,
reduced resource utilization. Therefore, patients who
fail to reachCD341 levels of.5/mL atmaximum stim-
ulation with G-CSF should benefit from the addition
of Plerixafor, and leukapheresis could be performed
10 to 12 hours after administration of Plerixafor.
Other PMs (borderline, relative PM) might also
benefit under certain circumstances, as collection of an
adequate amount of CD 34’ cells for tandem and even
triple transplantations need to be considered within
the overall treatment strategy of specific subgroups of
patients. Our experimental data indicated that the com-
binatorial approach might induce a more primitive and
eventually a different stemcell population that possesses
higher potentials [55,56]. Whether these additional
populations have an impact for the long-term outcome
must be addressed in future studies.ACKNOWLEDGMENTS
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